Economic evaluation of pharmacogenomic testing: Lessons from psychiatric pharmacogenomics

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Although pharmacogenomics has the potential to personalize drug therapy, economic evaluations showing clinical benefits and cost-effectiveness would go a long way to facilitate implementation. Testing of single genes has shown some benefits as well as limitations, and some investigators advocated the use of combinatorial pharmacogenomics approach. In addition, debates continue regarding the most appropriate way of evaluating cost-benefits. Review of alternative approaches to assessing clinical validity and utility, as well as cost-effectiveness of pharmacogenomics testing within the psychiatric discipline, show some promises and progress, as well as questions to be addressed, for these two important aspects of pharmacogenomics testing.

Original languageEnglish (US)
Title of host publicationPharmacogenomics
Subtitle of host publicationChallenges and Opportunities in Therapeutic Implementation
PublisherElsevier
Pages385-394
Number of pages10
ISBN (Electronic)9780128126264
DOIs
StatePublished - Jan 1 2018

Keywords

  • Clinical utility
  • Clinical validity
  • Combinatorial
  • Cost-benefit analysis
  • Economic outcomes
  • Personalized medicine
  • Pharmacogenomics
  • Psychiatry

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Economic evaluation of pharmacogenomic testing: Lessons from psychiatric pharmacogenomics'. Together they form a unique fingerprint.

Cite this